Acuitas: (noun) insight, perception, sharpness.

FEATURED

NEWS: DEVELOPMENT OF A NUCLEOSIDE-MODIFIED mRNA VACCINE AGAINST CLADE 2.3.4.4b H5 HIGHLY PATHOGENIC AVIAN INFLUENZA VIRUS (MAY 2024)

Congratulations to Steven Fan, co-author of a recent study featured in Nature Communications. He collaborated with scientists from Scott Hensley’s group at the University of Pennsylvania demonstrating that a monovalent mRNA-LNP vaccine expressing 2.3.4.4b H5 is immunogenic and protective in pre-clinical animal models. Click to read more info.

NEWS: ASGCT ANNUAL MEETING NEWS RELEASE (MAY 2024)

As the global leader in lipid nanoparticle delivery systems, Acuitas scientists, Dr. Ying Tam and Sean Semple, delivered poster presentations at the American Society of Gene + Cell Therapy Annual Meeting. Click to read the poster presentations.

NEWS: MRNA-LNP VACCINE-INDUCED CD8+ T-CELLS PROTECT MICE FROM LETHAL SARS-COV-2 INFECTION IN THE ABSENCE OF SPECIFIC ANTIBODIES (APR 2024)

Congratulations to Ying Tam and Molly Sung, co-authors of a recent study featured in Molecular Therapy. They collaborated with scientists from Thomas Jefferson University using mouse-adapted SARS-CoV-2 virus (MA30) in C57BL/6 mice, showing that CD8+ T cells are unnecessary for the intrinsic resistance of female or the susceptibility of male mice to lethal SARS-CoV-2 infection. Click to read more info.

OTHER NEWS

Video Alert
News Alert
  • May. 3, 2024 – Click to see a news release on Acuitas scientists, Dr. Ying Tam and Sean Semple, delivering poster presentations at the American Society of Gene + Cell Therapy Annual Meeting. More >
  • Apr. 11, 2024 – Click to see a news release regarding Acuitas Therapeutics being named one of Canada’s Top Small & Medium Employers (2024). More >
  • Feb. 13, 2024 – Click to see a news release regarding Acuitas Therapeutics being named one of BC’s Top Employers of 2024. More >
  • Dec. 20, 2023 – Click to see a news release regarding the appointment of Miranda Lam, Chief Legal Officer & Vice President, Business Development at Acuitas, as King’s Counsel in British Columbia. More >
  • Nov. 6, 2023 – Click to see a news release regarding the appointment of Dr. Ghania Chikh as Senior Director, Vaccine Development. More >
  • Jan. 26, 2023 – Click to see a news release regarding Acuitas President & CEO, Dr. Thomas Madden, being named a Canadian National Winner in the EY Entrepreneur of the year program. More >
  • Nov. 30, 2022 – Click to see a news release regarding Acuitas Therapeutics co-authoring a study that shows early promise for an mRNA vaccine targeting all known flu strains. More >
  • Sep. 29, 2022 – Click to see a news release regarding President & CEO, Dr. Thomas Madden, receiving BIOTECanada’s 2022 Gold Leaf Award in the Game Changing Industry Leadership category. More >
  • Aug. 5, 2022 – Click to see a news release regarding Michael Artley joining Acuitas Therapeutics as Senior Director of Information Technology. More >
  • Jul. 13, 2022 – Click to see a news release regarding Acuitas Therapeutics’ President & CEO, Dr. Thomas Madden, being named a Pacific winner in the EY Entrepreneur of the Year Award Program. More >
  • Jul. 8, 2022 – Click to see a news release regarding Acuitas Therapeutics being named this year’s recipient of Life Sciences BC’s Company of the Year award. More >
  • Apr. 27, 2022 – Click to see a news release regarding the founders of Acuitas Therapeutics, Drs. Pieter Cullis, Michael Hope and Thomas Madden, being named as Governor General’s Innovation Award recipients. More >
  • Apr. 4, 2022 – Click to see a news release regarding Abi Coman-Walker’s promotion to Chief Operating Officer. More >
  • Mar. 7, 2022 – Click to see a news release regarding an Acuitas Therapeutics donation to the Canadian Red Cross to support humanitarian efforts in Ukraine. More >
  • Jan. 31, 2022 – Click to see a news release regarding an Acuitas Therapeutics sponsorship agreement with the Greater Vancouver Regional Science Fair. More >
  • Jan. 24, 2022 – Click to see a news release regarding an Acuitas Therapeutics partnership agreement with Science World, Vancouver. More >
  • Jan. 17, 2022 – Click to see a news release regarding an Acuitas Therapeutics sponsorship agreement with the Vancouver Athletic Football Club. More >
  • Jan. 12, 2022 – Click to see a news release regarding Miranda Lam joining Acuitas Therapeutics as Chief Legal Officer & Sr. Director, Business Development. More >
  • Jan. 10, 2022 – Click to see a news release regarding Pfizer entering into an agreement with Acuitas for use of our lipid nanoparticle delivery system for mRNA vaccines and therapeutics. More >
  • Jan. 4, 2022 – Click to see a news release regarding Acuitas co-founder Dr. Pieter Cullis named an Officer of the Order of Canada. More >
  • Nov. 25, 2021 – Click to see a news release regarding Acuitas co-founder Dr. Pieter Cullis named a co-winner of the 2021 Prince Mahidol Award for medicine. More >
  • Sep. 23, 2021 – Click to see a news release regarding Acuitas Therapeutics receiving the Global Impact Award from Life Sciences BC. More >
  • Jul. 27, 2021 – Click to see a news release regarding Steve Arns joining Acuitas Therapeutics as the Director of Chemistry. More >
  • May 19, 2021 – Click to see a news release regarding publication of Acuitas research results in the prestigious journal Nature Biotechnology, from the company’s work as part of a collaboration with Dr. Schwank. More >
  • May 19, 2021 – Click to see a news release regarding publication of Acuitas research results in the prestigious journal Nature, from the company’s work as part of a collaboration with Verve Therapeutics, Inc. More >
  • Apr. 5, 2021 – Click to see a news release regarding Abi Coman-Walker joining Acuitas Therapeutics as the Finance & Operations Senior Director. More >
  • Feb. 5, 2021 – Click to see a news release regarding Dr. Madden’s participation in a panel led by the prestigious Gairdner Foundation. More >
  • Dec. 9, 2020 – Click to see a news release regarding our partner, BioNTech (with Pfizer), on the Health Canada emergency use authorization of their COVID-19 vaccine. Our proprietary lipid nanoparticles are an important aspect of BioNTech’s mRNA vaccine. More >
  • Nov. 9, 2020 – Click to see a news release regarding our partner, BioNTech, and their Phase 3 data for a COVID-19 vaccine. Our proprietary lipid nanoparticles are an important aspect of BioNTech’s mRNA vaccine. More >
  • Nov. 3, 2020 – Click to see a news release regarding our partner, CureVac, and their clinical trial data for a COVID-19 vaccine. Our proprietary lipid nanoparticles are an important aspect of CureVac’s mRNA vaccine. More >
  • Jul. 1, 2020 – Click to see a news release regarding our partner, BioNTech, and their clinical trial data for a COVID-19 vaccine. Our proprietary lipid nanoparticles are an important aspect of BioNTech’s mRNA vaccine. More >
  • Mar. 30, 2020 – Our President and CEO, Dr. Thomas Madden, has been inducted into the very prestigious American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. More >
Publication Alert
  • May 23, 2024 – Collaboration with Colleen Furey and colleagues demonstrating that a monovalent mRNA-LNP vaccine expressing 2.3.4.4b H5 is immunogenic and protective in pre-clinical animal models (Nature Communications 2024). More >
  • April 23, 2024 – Collaboration with Barton F. Haynes studying a process for developing boosting immunogens for HIV broadly neutralizing antibody induction (Cell Host & Microbe 2024). More >
  • April 10, 2024 – Collaboration with Luis J. Sigal studying mRNA-LNP vaccine-induced CD8+ T-cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies (Molecular Therapy 2024). More >
  • Apr 2, 2024 – Collaboration with Sarah Hedtrich exploring mechanisms of lipid nanoparticle-mucus interactions in healthy and cystic fibrosis conditions. (PubMed 2024). More >
  • March 21, 2024 – Collaboration with Hamideh Parhiz of the University of Pennsylvania studying how IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation (Proceedings of the National Academy of Sciences of the United States of America 2024). More >
  • March 18, 2024 – Collaborating with Patrick Glassman, the co-authors developed a physiologically-based pharmacokinetic/pharmacodynamic model for systemically administered mRNA-containing lipid nanoparticles in mice (Molecular Therapy 2024). More >
  • March 6, 2024 – Collaboration with Oscar A. Marcos-Contreras targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke. (Molecular Therapy 2024). More >
  • February 15, 2024 – Collaboration with Robert Birdsall monitoring stability indicating impurities and aldehyde content in lipid nanoparticle raw material and formulated drugs (Journal of Chromatography B 2024). More >
  • January 4, 2024 – Collaboration with Jaqueline Matias studying how 19ISP can interfere with the fecundity of adult I. scapularis, and this finding opens new strategies to reduce tick populations in endemic areas. (Scientific Reports 2024). More >
  • December 14, 2023 – Collaboration with Nawapol Kunkeaw studying a safe and effective messenger RNA vaccine to eliminate P. vivax malaria (NPJ Vaccines 2023). More >
  • July 27, 2023 – Collaboration with Laura Breda and Hamideh Parhiz studying the delivery of messenger RNA to bone marrow stem cells by intravenous injection in lipid nanoparticles, facilitating both gene editing and bone marrow transplantation (Science 2023). More >
  • May 25, 2023 – Collaboration with Magnus Hoffmann and Pamela Bjorkman studying the impact of presenting a natural infection-mimicking technology that combines features of mRNA- and protein nanoparticle-based vaccines through encoding self-assembling enveloped virus-like particles (Cell 2023). More >
  • Feb. 17, 2023 – Collaboration with Elias Haddad’s group at Drexel University College of Medicine studying the impact of the LNP component of mRNA-based vaccine, on anti-viral pathways and immune function of cells from young and aged individuals (Nature 2023). More >
  • Jan. 16, 2023 – Collaboration with Gabriel Victora and Arien Schiepers on molecular fate-mapping of serum antibody responses following repeat immunizations with mRNA LNP (Nature 2023). More >
  • Nov. 24, 2022 – Collaboration with Scott Hensley’s group at UPenn on the development of a multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes (Science 2022). More >
  • Aug. 9, 2022 – Collaboration with Dr. Pardi on the development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses (Nature Communications 2022). More >
  • May 16, 2022 – Collaboration with Precision BioSciences on a study targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo (Molecular Therapy 2022). More >
  • Mar. 15, 2022 – Collaboration with Zekun Mu and Dr. Barton Haynes of Duke Human Vaccine Institute on a study that shows mRNA vaccine technology can be used for HIV vaccines (Cell Reports 2022). More >
  • Jan. 6, 2022 – Collaboration with University of Pennsylvania investigators Jonathan Epstein and Drew Weissman in designing an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (Science 2022). More >
  • Jun. 21, 2021 – Collaboration with Dr. Angov in the development of messenger RNA expressing PfCSP that induces functional, protective immune responses against malaria in mice (Walter Reed Army Institute of Research 2021). More >
  • May 19, 2021 – Collaboration with Dr. Schwank in the development of in vivo adenine base editing of PCSK9 in macaques that reduce LDL cholesterol levels (Nat Biotech 2021). More >
  • May 19, 2021 – Collaboration with Verve Therapeutics, Inc. in the development of non-viral lipid nanoparticle (LNP) delivery technologies for single-course in vivo, liver-targeted gene editing treatments for cardiovascular disease, the leading cause of death worldwide (Nature 2021). More >
  • Jan. 27, 2021 – Collaboration with Dr. Weissman in the development of murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA (Nature Communications 2021). More >
  • Jan. 26, 2021 – Collaboration with Dr. Schwank in the development of in vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA (Nature Biomedical Engineering 2021). More >
  • Dec. 24, 2020 – Collaboration with Dr. Weissman in the development of D614G spike mutation that increases SARS CoV-2 susceptibility to neutralization (Cell Host Microbe 2020). More >
  • Dec. 1, 2020 – Collaboration with Dr. Locci in the development of potent antigen-specific germinal center responses associated with neutralizing antibody generation in SARS-CoV-2 mRNA vaccines (Immunity 2020). More >
  • Aug. 25, 2020 – Collaboration with Dr. Pardi in the development of nucleoside-modified mRNA vaccines against SARS-CoV-2 (Immunity 2020). More >
  • Jul. 9, 2020 – Collaboration with Dr. Shattock in the development of a SARS-CoV2 vaccine using self-amplifying RNA encapsulated in LNP (Nat Commun 2020). More >
  • Jun. 30, 2020 – Collaboration with Dr. Nachbagauer in the development of a universal influenza virus vaccine (Mol Ther 2020). More >
  • Jun. 30, 2020 – Collaboration with Dr. Kurtis in the development of a vaccine based on PfGARP that partially protects subjects against malaria challenge (Nature 2020). More >
  • Jan. 30, 2020 – Collaboration with Dr. Muzykantov in the development of mRNA-LNP targeting cerebral Vasculature (Proc Natl Acad Sci U S A. 2020). More >
  • Jan. 30, 2020 – Collaboration with Dr. Hensley in the development of mRNA-LNP vaccine for infants (Sci Transl Med. 2020). More >
  • Sep. 20, 2019 – Collaboration with Dr. Sanders in the delivery of self-amplifying mRNA with LNPs (Mol Ther Nucleic Acids 2019). More >
  • Apr. 12, 2019 – Collaboration with Dr. Weissman in the development of mRNA-LNP for HIV vaccine (Mol Ther Nucleic Acids 2019). More >
  • Apr. 12, 2019 – Collaboration with Dr. Lee and colleagues in the development of ZFN mRNA-LNP for in vivo genome editing (Mol Ther 2019). More >
  • Nov. 22, 2018 – Collaboration with Dr. Muzykantov in the development of targeting mRNA-LNP (J Control Release 2018 Dec 10;291:106-115). More >
  • Aug. 22, 2018 – Collaboration with Dr. Weissman in the development of broadly protective/universal influenza virus vaccine using mRNA-LNP (Nat Commun. 2018 Aug. 22; 9(1): 3361). More >